Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00925548 · ClinicalTrials.gov registry record · Phase 3
STRIDE - STimulating Immune Response In aDvanced brEast Cancer
A Phase 3 study, sponsored by EMD Serono.
- Terminated
- Registry status
- Phase 3
- Development phase
- 16
- Enrollment target
NCT00925548: Clinical Trial Phase 3 study, sponsored by EMD Serono.
NCT00925548 is a Phase 3 study that was terminated before completion, run by EMD Serono. The registered enrollment target is 16 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00925548, a Phase 3 study, was terminated before completion, sponsored by EMD Serono.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 16 participants
- Enrollment target
Study Summary
EMD Serono has decided to permanently terminate the trial EMR 200038-010 (STRIDE) in the indication of breast cancer following the clinical hold on the investigational new drug application for tecemotide (L-BLP25).
Primary Outcome
PFS was defined as the duration from randomization to first observation of progressive disease (PD) as confirmed by the independent radiological review or death.
Interventions
- DRUG cyclophosphamide
- BIOLOGICAL Tecemotide (L-BLP25) and Hormonal Treatment
- BIOLOGICAL Placebo of tecemotide (L-BLP25) and Hormonal Treatment
- DRUG sodium chloride (NaCl)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2009-09 |
| Est. Completion | 2010-08 |
| Phase | Phase 3 |
Why NCT00925548 stopped before completion
NCT00925548 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 4 interventions - of which cyclophosphamide is the first listed.
NCT00925548 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00925548 about?
NCT00925548 is a clinical study titled "STRIDE - STimulating Immune Response In aDvanced brEast Cancer". EMD Serono has decided to permanently terminate the trial EMR 200038-010 (STRIDE) in the indication of breast cancer following the clinical hold on the investigational new drug application for tecemotide (L-BLP25).
What is the current status of trial NCT00925548?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 16 participants. The study started on 2009-09. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00925548?
The interventions under investigation include: cyclophosphamide (DRUG), Tecemotide (L-BLP25) and Hormonal Treatment (BIOLOGICAL), Placebo of tecemotide (L-BLP25) and Hormonal Treatment (BIOLOGICAL), sodium chloride (NaCl) (DRUG).
Who is sponsoring clinical trial NCT00925548?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00925548's enrollment target sits among peer trials
16 1974th of 2000 higher than 24 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia